Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 March 2025 | Story Litha Banjatwa | Photo Supplied
Fiesta winners 2025
Ons wag vir Godot shines at the 2025 kykNET Fiësta Awards, winning three major accolades and cementing UFS’s reputation for world-class theatre excellence.

Ons wag vir Godot, a groundbreaking stage production from the University of the Free State (UFS) Department of Drama and Theatre Arts, was one of the biggest winners at the 2025 kykNET Fiësta Awards, which celebrate the best of Afrikaans theatre.

The awards ceremony was held at the Kirstenbosch National Botanical Garden in Cape Town on 27 February 2025.

Ons wag vir Godot, an Afrikaans translation of Irish writer Samuel Beckett’s celebrated 1953 play Waiting for Godot, won three of its four nominations: Best Director for Dion van Niekerk, Best Translation for Naomi Morgan, and Best Supporting Actor for Gerben Kamper. This haul positioned Ons wag vir Godot as the second biggest winner of the evening, and marked an unprecedented achievement for a Free State production at the Fiësta Awards.

This success builds upon the play’s earlier triumphs at the Free State Arts Festival, where it received accolades for Best Director, Best Translation, Best Supporting Actor (Peter Taljaard), and Best Ensemble.

Director Dion van Niekerk said what set Ons wag vir Godot apart was its unique origin: it is the first Afrikaans translation of Beckett's masterpiece directly from the French original. Securing the translation rights was no small feat, requiring a special appeal to the notoriously selective Samuel Beckett Estate.

“The production’s greatest challenge lay in making the play accessible to a South African audience,” Van Niekerk said. “We aimed to find a stage language with visual imagery that would situate the play within a recognisable South African context."

This was achieved through Naomi Morgan’s “immaculate translation work, which captured the existential concerns of the play with precisely the right Afrikaans vocabulary and turns of phrase”. The production team further grounded the play in South African reality through the creation of characters, setting, and costuming that evoked the stark beauty of the Karoo landscape.

The success of Ons wag vir Godot has profound implications for the UFS Department of Drama and Theatre Arts. It firmly establishes the department among the nation’s leading drama institutions, showcasing its ability to contribute high-quality, meaningful work to the South African artistic landscape. “This production highlights the importance of performing translated classics,” Van Niekerk said. “Works like Waiting for Godot are part of the canon of great international theatrical works. South Africa was banned from producing this play during apartheid, and it has been rarely seen since, predominantly in English.” This production, therefore, offers Afrikaans-speaking South Africans and others a unique opportunity to engage with Beckett’s timeless work.

The impact of this success extends to the department’s students. Sibabalwe Jokani, a student cast member, shared in the nominations for Best Ensemble at both the Free State Festival and Fiësta Awards. Jokani said the play’s success has inspired the student body and reaffirmed the department’s commitment to high standards and industry access.

When asked about the future of Afrikaans theatre, Van Niekerk said, “This production will hopefully inspire others to continue to reconsider the value that great theatrical works that have been created in other languages might have in a contemporary Afrikaans context.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept